Esperion raises $33m for LDL-lowering drug
This article was originally published in Scrip
Executive Summary
Esperion Therapeutics raised $33 million in a preferred stock financing to fund mid-stage clinical trials for ETC-1002, an oral small molecule with a novel mechanism of action that lowers low-density lipoprotein (LDL) cholesterol without the myalgia and impacts on glycemic control that can be associated with statins.